Table 2.

Percentage of patients with an average of ≥3 SCBMS per week during weeks 1–12

	Placebo(N = 252)	Prucalopride(N = 249)	P value*
Primary efficacy endpoint
Responders, n (%)	26 (10.3)	83 (33.3)	<0.001
Subgroups, n/N (%)
Race
Asian	25/231 (10.8)	78/232 (33.6)	<0.001
Non-Asian	1/21 (4.8)	5/17 (29.4)	0.031
Gender
Female	24/223 (10.8)	77/227 (33.9)	<0.001
Male	2/29 (6.9)	6/22 (27.3)	0.022
Age group
18–40 years	11/107 (10.3)	41/115 (35.7)	<0.001
41–65 years	15/145 (10.3)	42/134 (31.3)	<0.001
Previous treatment for constipation
Not used	13/75 (17.3)	33/66 (50.0)	<0.001
Used and adequate	1/40 (2.5)	15/43 (34.9)	<0.001
Used and inadequate	12/137 (8.8)	35/140 (25.0)	<0.001

SCBM, spontaneous complete bowel movement.

^*Levels of significance: prucalopride vs placebo.